{
  "trial_id": "NCT03976843",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Histologically proven prostate adenocarcinoma confirmed by a CLIA certified laboratory.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Prostate cancer with high risk features defined as: Gleason 8 and higher OR PSA > 20 ng/mL OR Clinical stage T3a (i.e. likely extraprostatic extension on MRI) or T3b.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Age greater than or equal to 18 years.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "ECOG performance status <2.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Adequate organ and marrow function as defined below: Hemoglobin greater than or equal to 9 g/dL, leukocytes greater than or equal to 3,000/mcL, platelets greater than or equal to 100,000/mcL.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Ability of subject to understand and the willingness to sign a written informed consent document.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Willingness and ability to undergo biopsy of radiotracer-avid lesion if feasible.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Willingness and ability to undergo multiparametric prostate MRI and 18F-DCFPyL PET/CT.",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Any investigational agents in the past 28 days prior to enrollment.",
      "label": "triggers",
      "evidence": "quote"
    },
    {
      "criterion": "Clinical stage T4 (tumor invades adjacent structures except seminal vesicles).",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Distant metastatic disease on conventional imaging studies (computed tomography (CT) of the abdomen and pelvis and 99mTc-methylene diphosphonate bone scan (bone scan)).",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Any prior hormone therapy used to treat prostate cancer, except limited androgen receptor antagonist therapy, defined as less than or equal to 3 days of treatment.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Any prior therapy for prostate cancer with surgery, radiation, and/or chemotherapy.",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "The patient has a history of lower urinary tract symptoms including frequency, urgency, weak stream, incomplete emptying and intermittent flow. He is otherwise healthy and has normal blood chemistry.",
  "_meta": {
    "topic_id": "24",
    "trial_id": "NCT03976843",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}